Albuterol Inhalation Aerosol

Compare Albuterol Inhalation Aerosol  to:
Compare
Compare

Generic Name for Albuterol Inhalation Aerosol

Albuterol 90 micrograms/inh; metered-dose aerosol.

Legal Classification:

Rx

Pharmacological Class for Albuterol Inhalation Aerosol

β2-agonist.

Manufacturer of Albuterol Inhalation Aerosol

Various generic manufacturers

Indications for Albuterol Inhalation Aerosol

Bronchospasm.

Adults and Children:

<4 years: not recommended. ≥4 years: 2 inh every 4–6 hrs as needed; 1 inh every 4 hrs may suffice. Exercise–induced bronchospasm: 2 inh 15 minutes before exercise.

Also:

Warnings/Precautions for Albuterol Inhalation Aerosol

Avoid excessive use. Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disease (eg, coronary insufficiency, arrhythmias, hypertension). Diabetes. Hyperthyroidism. Seizure disorders. Reevaluate periodically. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for Albuterol Inhalation Aerosol

Avoid MAOIs, tricyclics within 14 days (increased cardiovascular effects). Oral sympathomimetics: not recommended. Antagonized by β-blockers. Monitor digoxin. Caution with other drugs that may lower serum potassium (eg, diuretics).

Adverse Reactions for Albuterol Inhalation Aerosol

Tremor, nervousness, headache, dizziness, hyperactivity, insomnia, weakness, tachycardia, epistaxis, hypokalemia, throat irritation (inh), paradoxical bronchospasm; immediate hypersensitivity reactions (eg, rash, urticaria, angioedema).

How is Albuterol Inhalation Aerosol supplied?

Contact supplier.

Related Disease:

Bronchospasm~bronchodilators

Related Resources

FDA warns of stolen Advair Diskus product

July 19, 2010

The FDA has warned healthcare professionals and consumers not to use certain Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhalers stolen from a distribution warehouse in 2009 which have been found recently in some pharmacies.

Glassia approved for treating alpha 1 antitrypsin deficiency

July 06, 2010

Kamada announced that the FDA has approved Glassia (alpha1-proteinase inhibitor liquid) for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (AATD).

Dulera approved for the treatment of asthma

June 24, 2010

Merck announced that the FDA has approved Dulera (mometasone furoate and formoterol fumarate dihydrate) inhalation aerosol for the treatment of asthma in patients ≥12 years of age.

Phase 2b study of Aerovant for the treatment of eosinophilic asthma

June 08, 2010

Aerovance Inc. announced top-line results from its Phase 2b trial demonstrating that Aerovant (pitrakinra) is effective in a pre-defined subset of patients with eosinophilic asthma.

AeroChamber Plus Flow-Vu anti-static valved holding chamber available

June 04, 2010

Forest Pharmaceuticals and Lupin Pharmaceuticals have made available the AeroChamber Plus Flow-Vu anti-static valved holding chamber for use with metered dose inhalers (MDI).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions